1. Scrip
  3. >>Clinical Trials

Another Blow For Anti-TIGITs As Merck’s Vibostolimab/Keytruda Combo Misses In Phase II NSCLC Trial

But Still Has Potential In Earlier Lines

 
• By Ayisha Sharma

Merck & Co’s combination treatment has disappointed in a challenging group of lung cancer patients, marking yet another setback for the increasingly precarious anti-TIGIT space even as some analysts say this is not the end of the road.  

Strings of thread wearing thin, just one string left to connect thread
Investor Sentiment On Anti-TIGITs Is Wearing Thin • Source: Shutterstock

A combination product containing Merck & Co., Inc.’s Keytruda plus its investigational anti-TIGIT therapy, vibostolimab, has missed the mark in a Phase II lung cancer trial, adding to a spate of disappointments in the TIGIT space, but some analysts remain hopeful about performance in earlier lines of disease.

The US major product candidate, known as MK-7684A, is a coformulation of 200mg of its blockbuster anti-PD-L1 drug Keytruda (pembrolizumab)...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D